Oral Breast Cancer Drug Wins Broader FDA Nod for ESR1-Mutated Disease

(Medage today) – The FDA has approved the antagonist of immluenting oral estrogen (inluriyo) for advanced / metastatic breast cancer mutated by ESR1 previously treated, the agency announced Thursday. Approval stipulates use in adults with …